Terns Pharmaceuticals

NSQ:TERN · US8808811074

PharmaceuticalsSmall

360° View

Value46

Price/Sales—

Price/Earnings97

Price/Book7

Dividend Yield1

Growth86

Revenue Growth—

Profit Growth27

Capital Growth10

TSR 52w98

Safety67

Leverage100

Liquidity3

Refinancing66

Combined98

Sentiment3

Analyst Opinions7

Pro Holdings1

Opinion Changes2

Market Pulse81

Profile

CountryUSA

IndustryPharmaceuticals

SizeSmall

TypePrivate Company

ExchangeNASDAQGS

Founded2016

Employees61

Websiteternspharma.com

ISINUS8808811074

Last UpdateApr 2, 2026

Index & Theme

HematologyOncologyEndocrinologyObesityHepatologyBiotechnologyHealth CareMedicalMedical DevicePharmaceutical

Description

Terns Pharmaceuticals, Inc. operates as a clinical-stage oncology company reimagining known biology to deliver high impact medicines. All product candidates in the company’s pipeline were internally discovered. The company’s lead oncology asset is T…

Analysis

Terns Pharmaceuticals's 360° View rank of 96 places it among the strongest overall — better than 96% of its true peers.

It's a growth standout (86) and on the expensive side (46). On safety it is financially sound (67), and the market shows skeptical sentiment (3). Taken together, its Combined rank of 98 reads as among the strongest overall.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Terns Pharmaceuticals with its peers

MBX Biosciences

NSQ:MBX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Structure Therapeutics

NMQ:GPCR

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Rapport Therapeutics

NMQ:RAPP

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Lipocine

NAQ:LPCN

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Oramed Pharmaceuticals

NAQ:ORMP

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Nektar

NAQ:NKTR

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →